(3.238.99.243)
Users online: 657    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2020, Volume : 13, Issue : 2
First page : ( 862) Last page : ( 866)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2020.00163.8

Using Simvastatin Mouthwash (0.6%, 1.2% and 1.8%) on the Improvement of Clinical Parameters in Patients with Chronic Periodontitis

Abdi Zeinab1, Roozegar Mohammad-Ali2, Beigi Sepideh3,*, Khorshidi Ali4, Azizian Mohammad5, Beigi Zahra6

1Assistant Professor of Periodontology, School of Dentistry, Ilam University of Medical Sciences, Ilam, Iran

2Associate Professor of Periodontology, School of Dentistry, Ilam University of Medical Sciences, Ilam, Iran

3Student of Dentistry, School of Dentistry, Ilam University of Medical Sciences, Ilam, Iran

4Assistant Professor of Epidemiology, School of Medicine, Psychosocial Injuries Research Center, Ilam University of Medical Sciences, Ilam, Iran

5Assistant Professor of Prosthodontics, School of Dentistry, Psychosocial Injuries Research Center, Ilam University of Medical Sciences, Ilam, Iran

6MD, School of Medicine, Psychosocial Injuries Research Center, Ilam University of Medical Sciences, Ilam, Iran

*Corresponding Author E-mail: havasian1991@gmail.com, mpvmpv559@gmail.com

Online published on 9 April, 2020.

Abstract

Periodontitis is a destructive disease that targets tooth supporting structures. Simvastatin (SMV) are inhibitors of HMG-COA reductase enzyme that have complex interaction with cholesterol metabolites, inflammatory mediators, hormones and bone metabolism, thus having direct and important effects on extent and severity of periodontitis. The present study aims to evaluate the in vivo effect of mouthwash of CHX and SMV (.6 and 1.2 and 1.8%) as a local drug-delivery agent on clinical parameters in chronic periodontitis. 50 patients were selected and categorized into five treatment groups. At initial appointment SRP were done and clinical parameters were measured and mouthwashes of SMV (0.6–1.2–1.8) and CHX and placebo distributed among groups. Measurement of clinical parameters after one month repeated for all groups and required data was collected and analyzed. SRP with SMV (0.6–1.2–1.8) significantly improve the clinical parameters (AL-BOP-PD). Mouthwash of SMV 1.2 and 1.8 and CHX in decrease of BOP and PD and AL has no significant differences (P>0.05). Mouthwash of SMV 1.2 and 1.8 and CHX has significantly differences in decrease of BOP and PD than SMV.06 and placebo (P<.05). SMV (0.6–1.2–1.8) and CHX has significantly differences in decease of AL than Normal saline. With due attention to inhibition of inflammatory cytokines with SMV on periodontitis, SMV can be good alternative for CHX in chronic periodontitis patients.

Top

Keywords

Chronic periodontitis-mouthwash-cytokine-simvastatin.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
490,291,242 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.